SCHEMBL14901213

SCHEMBL14901213

COc1cc(Nc2ccc3ncc(-c4cccnc4)nc3n2)cc(OC)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 5/20 0.53
MAPK1 P28482 3/20 0.53
MAPK8 P45983 3/20 0.53
MAPK9 P45984 3/20 0.53
MAPK10 P53779 3/20 0.53
BRAF P15056 2/20 0.50
IGF1R P08069 2/20 0.49
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
MAPT P10636 1/20 0.46
ATR Q13535 2/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
PRKD3 O94806 1/20 0.45
PRKCG P05129 1/20 0.45
PRKCB P05771 1/20 0.45
LCK P06239 1/20 0.45
PRKCA P17252 1/20 0.45
PRKCH P24723 1/20 0.45
PRKCI P41743 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14901118 0.89 MAPK1 (0.53) PIK3CAMAPK1MAPK8MAPK9MAPK10
SCHEMBL14901221 0.88 MAPK1 (0.53) PIK3CAMAPK1MAPK8MAPK9MAPK10
SCHEMBL14901215 0.83 ATR (0.44) PIK3CAMAPK1MAPK8MAPK9MAPK10
SCHEMBL16421990 0.82 FGFR3 (0.65) MAPK1BRAFMEN1KMT2AMAPT
SCHEMBL14905514 0.82 FGFR3 (0.52) PIK3CAMAPK1MAPK8MAPK9MAPK10
SCHEMBL14901143 0.81 MAPK1 (0.51) PIK3CAMAPK1MAPK8MAPK9MAPK10
SCHEMBL16126910 0.80 FGFR3 (0.51) PIK3CAMAPK1MAPK8MAPK9MAPK10
SCHEMBL5759671 0.76 PDGFRB (0.55) PIK3CAMAPK1MAPK8MAPK9MAPK10
SCHEMBL17175551 0.75 FGFR3 (0.54) PIK3CAMAPK1IGF1RMEN1KMT2A
SCHEMBL14901148 0.74 FGFR3 (0.46) PIK3CAMAPK1MAPK8MAPK9MAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2776435-B1 ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES ASTEX THERAPEUTICS LTD (GB) 2018-06-27 EP disclosed
US-10004733-B2 2018-06-26 US disclosed
US-20160235744-A1 SUBSTITUTED PYRIDO[2,3-b]PYRAZINES AS FGFR KINASE INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2016-08-18 US disclosed
US-9309242-B2 Substituted pyrido[2,3-b]pyrazines as FGFR kinase inhibitors ASTEX THERAPEUTICS LTD (GB) 2016-04-12 US disclosed
US-20140288053-A1 ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES ASTEX THERAPEUTICS LIMITED (GB) 2014-09-25 US disclosed
WO-2013061080-A1 ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES ASTEX THERAPEUTICS LIMITED (GB) 2013-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10004733-B2 SDHB, SDHA, NDUFS5 PIK3CA 580/4885MAPK1 2681/4885MAPK8 3344/4885
US-20140288053-A1 ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES FGFR1, FGFR2, FGFR4 PIK3CA 83/4885MAPK1 322/4885MAPK8 511/4885
US-20160235744-A1 SUBSTITUTED PYRIDO[2,3-b]PYRAZINES AS FGFR KINASE INHIBITORS FGFR1, FGFR2, FGFR3 PIK3CA 55/4885MAPK1 333/4885MAPK8 528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.